Analysts Are Neutral on These Healthcare Stocks: Seagen (SGEN), Crispr Therapeutics AG (CRSP)

Analysts fell to the sidelines weighing in on Seagen (SGEN – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Merck & Company (MRK – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Seagen (SGEN) In a report issued on July 29, Kennen MacKay from RBC Capital maintained a Hold rating on Seagen, with a price target of $148.00. The company's shares closed last Friday at $153.39. According to TipRanks.com, MacKay is a 4-star analyst with an average return of 12.9% and a 56.3% success rate. MacKay covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Acceleron Pharma, and Agios Pharma. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seagen with a $187.00 average price target, which is a 23.0% upside from current levels. In a report issued on July 16, Morgan Stanley also maintained a Hold rating on the stock with a $167.00 price target. See today’s analyst top recommended stocks >> Crispr Therapeutics AG (CRSP) RBC Capital analyst Luca Issi maintained a Hold rating on Crispr Therapeutics AG on July 30 and set a price target of $117.00. The company's shares closed last Friday at $121.02. According to TipRanks.com, Issi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.7% and a 31.3% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Intellia Therapeutics. Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $163.22, representing a 33.3% upside. In a report issued on July 30, Stifel Nicolaus also maintained a Hold rating on the stock with a $139.00 price target. Merck & Company (MRK) In a report issued on July 29, Daniel Busby from RBC Capital maintained a Hold rating on Merck & Company, with a price target of $80.00. The company's shares closed last Friday at $76.87. According to TipRanks.com, Busby is a 1-star analyst with an average return of -6.1% and a 33.3% success rate. Busby covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Verrica Pharmaceuticals, and Pacira Pharmaceuticals. Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $93.57. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on SGEN: Wall Street Analysts Are Bullish on Top Technology Picks Analysts Conflicted on These Conglomerates Names: Norfolk Southern (NSC), IDEX (IEX) and Fortune Brands (FBHS) Analysts Offer Insights on Materials Companies: Sherwin-Williams Company (SHW), West Fraser Timber Co (WFG) and Enviva (EVA) Analysts Offer Insights on Financial Companies: S&P Global (SPGI), Mastercard (MA) and Camden Property (CPT) Analysts Offer Insights on Consumer Goods Companies: Shopify (SHOP), Procter & Gamble (PG) and Nestlé SA (OtherNSRGF) The post Analysts Are Neutral on These Healthcare Stocks: Seagen (SGEN), Crispr Therapeutics AG (CRSP) appeared first on TipRanks Financial Blog.

Analysts fell to the sidelines weighing in on Seagen (SGEN – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Merck & Company (MRK – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Seagen (SGEN)

In a report issued on July 29, Kennen MacKay from RBC Capital maintained a Hold rating on Seagen, with a price target of $148.00. The company's shares closed last Friday at $153.39.

According to TipRanks.com, MacKay is a 4-star analyst with an average return of 12.9% and a 56.3% success rate. MacKay covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Acceleron Pharma, and Agios Pharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seagen with a $187.00 average price target, which is a 23.0% upside from current levels. In a report issued on July 16, Morgan Stanley also maintained a Hold rating on the stock with a $167.00 price target.

Crispr Therapeutics AG (CRSP)

RBC Capital analyst Luca Issi maintained a Hold rating on Crispr Therapeutics AG on July 30 and set a price target of $117.00. The company's shares closed last Friday at $121.02.

According to TipRanks.com, Issi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.7% and a 31.3% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Intellia Therapeutics.

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $163.22, representing a 33.3% upside. In a report issued on July 30, Stifel Nicolaus also maintained a Hold rating on the stock with a $139.00 price target.

Merck & Company (MRK)

In a report issued on July 29, Daniel Busby from RBC Capital maintained a Hold rating on Merck & Company, with a price target of $80.00. The company's shares closed last Friday at $76.87.

According to TipRanks.com, Busby is a 1-star analyst with an average return of -6.1% and a 33.3% success rate. Busby covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $93.57.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SGEN:

  • Wall Street Analysts Are Bullish on Top Technology Picks
  • Analysts Conflicted on These Conglomerates Names: Norfolk Southern (NSC), IDEX (IEX) and Fortune Brands (FBHS)
  • Analysts Offer Insights on Materials Companies: Sherwin-Williams Company (SHW), West Fraser Timber Co (WFG) and Enviva (EVA)
  • Analysts Offer Insights on Financial Companies: S&P Global (SPGI), Mastercard (MA) and Camden Property (CPT)
  • Analysts Offer Insights on Consumer Goods Companies: Shopify (SHOP), Procter & Gamble (PG) and Nestlé SA (OtherNSRGF)

The post Analysts Are Neutral on These Healthcare Stocks: Seagen (SGEN), Crispr Therapeutics AG (CRSP) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Analysts Offer Insights on Utilities Companies: Fortis (FTS), Callon (CPE) and Ovintiv (OVV)

Analysts fell to the sidelines weighing in on Fortis (FTS – Research Report), Callon (CPE – Research Report) and Ovintiv (OVV – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Fortis (FTS) RBC Capital analyst Maurice Choy maintained a Hold rating on Fortis on July 30 and set a price target of C$59.00. The company's shares closed last Friday at $45.34. According to TipRanks.com, Choy is a 4-star analyst with an average return of 23.9% and a 85.2% success rate. Choy covers the Utilities sector, focusing on stocks such as TransAlta, ATCO Ltd., and Emera. Currently, the analyst consensus on Fortis is a Hold with an average price target of $46.33, implying a 2.0% upside from current levels. In a report issued on July 18, J.P. Morgan also maintained a Hold rating on the stock with a C$58.00 price target. See today’s analyst top recommended stocks >> Callon (CPE) In a report issued on July 28, Scott Hanold from RBC Capital maintained a Hold rating on Callon, with a price target of $54.00. The company's shares closed last Friday at $39.36. According to TipRanks.com, Hanold is a 3-star analyst with an average return of 4.1% and a 42.4% success rate. Hanold covers the Utilities sector, focusing on stocks such as Centennial Resource Development, Whiting Petroleum Corporation, and California Resources Corp. Callon has an analyst consensus of Hold, with a price target consensus of $52.43, implying a 31.6% upside from current levels. In a report issued on July 19, Citigroup also maintained a Hold rating on the stock with a $45.00 price target. Ovintiv (OVV) RBC Capital analyst Gregory Pardy maintained a Hold rating on Ovintiv on July 28 and set a price target of $36.00. The company's shares closed last Friday at $25.66. According to TipRanks.com, Pardy is a 4-star analyst with an average return of 8.8% and a 49.6% success rate. Pardy covers the Utilities sector, focusing on stocks such as Canadian Natural, Vermilion Energy, and Cenovus Energy. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ovintiv with a $40.12 average price target, which is a 55.0% upside from current levels. In a report issued on July 20, Raymond James also initiated coverage with a Hold rating on the stock with a $35.00 price target. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on FTS: Analysts Are Neutral on These Healthcare Stocks: Seagen (SGEN), Crispr Therapeutics AG (CRSP) Wall Street Analysts Are Bullish on Top Technology Picks Analysts Conflicted on These Conglomerates Names: Norfolk Southern (NSC), IDEX (IEX) and Fortune Brands (FBHS) Analysts Offer Insights on Materials Companies: Sherwin-Williams Company (SHW), West Fraser Timber Co (WFG) and Enviva (EVA) Analysts Offer Insights on Financial Companies: S&P Global (SPGI), Mastercard (MA) and Camden Property (CPT) The post Analysts Offer Insights on Utilities Companies: Fortis (FTS), Callon (CPE) and Ovintiv (OVV) appeared first on TipRanks Financial Blog.

Analysts fell to the sidelines weighing in on Fortis (FTS – Research Report), Callon (CPE – Research Report) and Ovintiv (OVV – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Fortis (FTS)

RBC Capital analyst Maurice Choy maintained a Hold rating on Fortis on July 30 and set a price target of C$59.00. The company's shares closed last Friday at $45.34.

According to TipRanks.com, Choy is a 4-star analyst with an average return of 23.9% and a 85.2% success rate. Choy covers the Utilities sector, focusing on stocks such as TransAlta, ATCO Ltd., and Emera.

Currently, the analyst consensus on Fortis is a Hold with an average price target of $46.33, implying a 2.0% upside from current levels. In a report issued on July 18, J.P. Morgan also maintained a Hold rating on the stock with a C$58.00 price target.

Callon (CPE)

In a report issued on July 28, Scott Hanold from RBC Capital maintained a Hold rating on Callon, with a price target of $54.00. The company's shares closed last Friday at $39.36.

According to TipRanks.com, Hanold is a 3-star analyst with an average return of 4.1% and a 42.4% success rate. Hanold covers the Utilities sector, focusing on stocks such as Centennial Resource Development, Whiting Petroleum Corporation, and California Resources Corp.

Callon has an analyst consensus of Hold, with a price target consensus of $52.43, implying a 31.6% upside from current levels. In a report issued on July 19, Citigroup also maintained a Hold rating on the stock with a $45.00 price target.

Ovintiv (OVV)

RBC Capital analyst Gregory Pardy maintained a Hold rating on Ovintiv on July 28 and set a price target of $36.00. The company's shares closed last Friday at $25.66.

According to TipRanks.com, Pardy is a 4-star analyst with an average return of 8.8% and a 49.6% success rate. Pardy covers the Utilities sector, focusing on stocks such as Canadian Natural, Vermilion Energy, and Cenovus Energy.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ovintiv with a $40.12 average price target, which is a 55.0% upside from current levels. In a report issued on July 20, Raymond James also initiated coverage with a Hold rating on the stock with a $35.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on FTS:

  • Analysts Are Neutral on These Healthcare Stocks: Seagen (SGEN), Crispr Therapeutics AG (CRSP)
  • Wall Street Analysts Are Bullish on Top Technology Picks
  • Analysts Conflicted on These Conglomerates Names: Norfolk Southern (NSC), IDEX (IEX) and Fortune Brands (FBHS)
  • Analysts Offer Insights on Materials Companies: Sherwin-Williams Company (SHW), West Fraser Timber Co (WFG) and Enviva (EVA)
  • Analysts Offer Insights on Financial Companies: S&P Global (SPGI), Mastercard (MA) and Camden Property (CPT)

The post Analysts Offer Insights on Utilities Companies: Fortis (FTS), Callon (CPE) and Ovintiv (OVV) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.